

Annals of the Rheumatic Diseases

The EULAR Journal

Leaders

- 401 The first annual EULAR Congress *L B A van de Putte, T L Vischer*
 401 Education to improve the health of the nation: Who should we educate? *A D Woolf, M Doherty*
 403 COPE guidelines on good publication practice *M Doherty, L B A van de Putte*
 404 Anti-TNF α : a new dimension in the pharmacotherapy of the spondyloarthropathies!? *J Braun, J Sieper*
 407 Do patients with osteoarthritis get the clinical research they need? *P C Göttsche*

Series on education series editors: A D Woolf, M Doherty

- 409 Rheumatology: What should all doctors know? *M Doherty, P Lanyon*

Review

- 414 Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint *J A Chard, D Tallon, P A Dieppe*

EULAR news

- 419 Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds
A Silman, L Klareskog, F Breedveld, B Bresnihan, R Maini, P van Riel, D Symmons

Notes/news

- 421 Forthcoming events

Book review

- 421 Rheumaderm: current issues in rheumatology and dermatology

Extended reports

- 422 Radiographic assessment of hip osteoarthritis progression: impact of reading procedures for longitudinal studies *G-R Auleley, B Giraudeau, M Dougados, P Ravaud*
 428 Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study *F Van den Bosch, E Kruithof, D Baeten, F De Keyser, H Mielants, E M Veys*
 434 Improved medical and surgical management of cervical spine disease in patients with rheumatoid arthritis over 10 years *J D Hamilton, M-M Gordon, I B McInnes, R A Johnston, R Madhok, H A Capell*
 439 Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment *A-K Ulfgren, L Gröndal, S Lindblad, M Khademi, O Johnell, L Klareskog, U Andersson*
 448 Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage *D Pfander, T Cramer, D Deuerling, G Weseloh, B Swoboda*
 455 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis *Y Yoshihara, H Nakamura, K Obata, H Yamada, T Hayakawa, K Fujikawa, Y Okada*
 462 Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies? *M Y Mok, V T Farewell, D A Isenberg*
 468 Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial *C H M van Jaarsveld, J W G Jacobs, M J van der Veen, A A M Blaauw, A A Kruize, D M Hofman, H L M Brus, G A van Albada-Kuipers, A H M Heurkens, E J ter Borg, H C M Haanen, C van Booma-Frankfort, Y Schenk, J W J Bijlsma, on behalf of the Rheumatic Research Foundation Utrecht, The Netherlands*
 478 A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature *S F Sørensen, O Slot, N Tvede, J Petersen*

Concise reports

- 483 Anticardiolipin autoantibodies in serum samples and cryoglobulins of patients with chronic hepatitis C infection *Z M Sthoeger, M Fogel, A Smirov, D Ergas, Y Lurie, D D Bass, D Geltner, S D H Malnick*
 487 An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use *S J Morton, R J Powell*

Correspondence

- 490 Matters arising
 490 Letters

This issue live and online
www.annrheumdis.com